

A Case Study of Severe Pneumonia Caused by mixed Infection of *Chlamydia Abortus* and *Influenza a* in a Female Patient

Dan Ye^{1,2}, Yuanyuan Li², Kangkang Yan¹, Wenzhong Peng²

¹Department of Pharmacy, Xi'an No.3 Hospital, the Affiliated Hospital of Northwest University, Xi'an, People's Republic of China; ²Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China

Correspondence: Wenzhong Peng, Department of Respiratory Medicine, Xiangya Hospital, Central South University, Xiangya Road No. 87, Kaifu District, Changsha, Hunan, 410008, People's Republic of China, Tel +86-0731-89753287, Fax +86-89753287, Email pengwenzhong@csu.edu.cn

Background: *Chlamydia abortus* is a zoonotic pathogen that causes miscarriage, stillbirth, and sepsis of pregnancy in pregnant women when it infects humans. However, it rarely causes pneumonia in humans.

Case Presentation: This case reports a case of severe pneumonia characterized by high fever and cough, and the disease rapidly progressed to dyspnea. The patient was treated with moxifloxacin and doxycycline. *Chlamydia abortus* was detected in bronchoscopy examination and bronchoalveolar lavage fluid (BALF) through metagenomic next-generation sequencing (mNGS)-DNA. A weak positive for *influenza A (H1N1)* antigen was also found in the throat swab tested. Subsequently, we added mabaloxyvir and replaced doxycycline with an intravenous infusion of omadacycline. After effective treatment, the patient developed a urinary tract infection, and the treatment plan was adjusted to meropenem combined with omadacycline. The patient's condition improved, and she was discharged on the 14th day of admission.

Conclusion: This is the first report of cases of non-pregnant female patients with *Chlamydia abortus* infection pneumonia. Consequently, infections with *Chlamydia abortus* can result in severe respiratory distress, disturbance of water and electrolyte balance, and abnormal liver function, which requires timely diagnosis and correct use of antibiotics by clinicians. Consequently, the mixed infection of *H1N1* and *Chlamydia abortus* aggravated the complexity of the condition and treatment. Combining tetracycline and quinolone is effective for treating severe pneumonia with *Chlamydia abortus* infection.

Keywords: chlamydia abortus, severe pneumonia, metagenomics next-generation sequencing, case report

Background

Chlamydia is a family of obligate intracellular Gram-negative bacteria consisting of more than 10 species belonging to the order Chlamydiales and the family Chlamydiaceae.¹ Notably, they are widely distributed worldwide and infect various hosts, including amoebae, insects, aquatic animals, reptiles, birds, and mammals.² The most common pathogens that infect humans are *Chlamydia psittaci*, *Chlamydia trachomatis*, and *Chlamydia pneumoniae*.³ *Chlamydia abortus* (*C. abortus*) is a zoonotic pathogen that primarily colonizes the placenta of ruminants such as goats, sheep, yaks, pigs, and horses.⁴ Human infections with *C. abortus* are infrequent. However, they can result in severe symptoms, such as abortion, stillbirth, gestational sepsis, and rarely pneumonia.⁴ Therefore, we report a case of severe pneumonia caused by *C. abortus* infection in a female patient diagnosed using next-generation metagenomic sequencing (mNGS). Further, we discuss the clinical characteristics, signs, laboratory examination, treatment protocol, and prognosis of this case to provide a clinical reference for the future.

Case Presentation

A previously healthy 60-year-old female was admitted to our tertiary academic center for influenza-like illness, headache, dry cough, and fever (40°C) within 14 days. Prior to admission, she sought medical attention at a local clinic. However,

the effectiveness of antipyretic drugs was not satisfactory. Seven days earlier, she experienced breathing difficulties that gradually worsened.

Upon admission, physical examination showed a temperature of 36.5°C, heart rate of 68/min, respiratory rate of 20/min, and blood pressure of 116/47 mmHg, SPO₂99% (with high flow humidified oxygen therapy, flow rate 35L/min, oxygen concentration 80%). Auscultation revealed dull percussion in both lungs, thick breathing sounds in both lungs and a few moist rales. Upon questioning the patient's son, we learned she fed chickens and ducks at home and had a history of contact with poultry.

Laboratory investigations revealed type I respiratory failure, disturbance of water and electrolyte balance (hyponatremia, hypokalemia), anemia, hypoproteinemia, abnormal liver function, increased NT-pro BNP, lactate dehydrogenase, procalcitonin, erythrocyte sedimentation rate (ESR), D-dimer, and fibrinogen (Table 1). Other investigations identified urine occult blood, ketone bodies and a negative COVID-19 nucleic acid test. Chest CT showed multiple patchy high-density shadows in both lungs, consolidation shadows in the upper lobes of both lungs, numerous small nodules in both lungs and bilateral pleural effusion (Figure 1).

Table 1 Initial Maternal Laboratory Results

Variable	Result	Reference range
Red blood cell count (10 ¹² /L)	3.36	3.8–5.1
Lymphocyte count (10 ⁹ /L)	0.3	1.1–3.2
Hemoglobin (g/L)	99	115–150
Neutrophilic percentage (%)	90.7	40–75
Lymphocyte percentage (%)	7	20–50
Eosinophil count (10 ⁹ /L)	0	0.02–0.52
Eosinophil percentage (%)	0	0.4–8
Total protein (g/L)	54.7	65–85
Albumin (g/L)	25.5	40–55
Direct bilirubin (umol/L)	8.1	0–6.8
Alanine aminotransferase (U/L)	104.3	7–40
Aspartate aminotransferase (U/L)	83.4	13–35
Alkaline phosphatase (U/L)	422.9	50–135
Glutamyl transpeptidase (U/L)	356.2	7–45
Lactic dehydrogenase (U/L)	418	120–250
Myoglobin (ug/L)	113.5	<70
D-dimer (mg/L)	2.75	0–0.5
Fibrinogen (g/L)	7.6	2–4
Potassium (mmol/L)	2.78	3.5–5.3
Sodium (mmol/L)	130.6	137–147
Chlorine (mmol/L)	93.1	99–110
Calcium (mmol/L)	1.68	2.11–2.52
Phosphorus (mmol/L)	0.56	0.85–1.51
Erythrocyte sedimentation rate (mm/h)	120	0–38
Procalcitonin (ng/mL)	0.92	0–0.046
NT-pro BNP	1731.1	0–900
Arterial blood gases		
%FiO ₂	60%	
pH	7.57	7.35–7.45
PCO ₂ (mm Hg)	30.8	35–45
PO ₂ (mm Hg)	75	80–105
HCO ₃ ⁻ (mmol/L)	28.3	22–26
BE (mmol/L)	6	–2–3




Figure 1 Multiple patchy high-density shadows and consolidation shadows of both lungs (CT image of the chest on 3th day before admission).

The patient was diagnosed with severe pneumonia, type I respiratory failure, hypoproteinemia, electrolyte disturbance (hyponatremia, hypokalemia), abnormal liver function, and mild anemia upon admission. Considering the patient had a history of contact with poultry, preliminary suspicion suggested that the patient may be infected with atypical pathogens. Then, the patient was treated with an intravenous infusion of moxifloxacin (0.4g qd) and oral doxycycline (0.1g q12h), supplemented with protecting gastric mucosa, anticoagulation, resolving phlegm, dilating bronchi, and maintaining water-electrolyte balance by improving the symptom of respiratory failure via oxygen inhalation.

On the second day of admission, the patient experienced a progressive decrease in blood oxygen saturation (oxygenation index of 74). As a result, the patient required intubation and ventilator (PCV, FiO₂ 70%, PEEP 14.0 cmH₂O). Repeated arterial blood-gas analysis showed a pH level of 7.47, PaCO₂ at 42mmHg, PaO₂ at 87mmHg, PO₂/FiO₂ at 124 mmHg, and blood lactate at 1.0mmol/L. Laboratory test results indicated a weak positive for *influenza A (H1N1)* antigen, and the patient was given oral antiviral treatment with 40mg of mabaloaxvir tablets. Bronchoalveolar lavage fluid (BALF) samples were sent for metagenomic next-generation sequencing (mNGS) -DNA detection to obtain more information on the pathogen. Only *C. abortus* was detected with a 1486 sequence number (85.53% of relative abundance) by mNGS-DNA tests of BALF (Figure 2). Thus, we replaced doxycycline with an intravenous infusion of omadacycline (0.1 qd), while the intravenous infusion of moxifloxacin (0.4g qd) treatment was continued.




Figure 2 The unique mapping reads of *Chlamydia abortus* was 1486. (Diagnosis of *C. abortus* infection using mNGS test).




Figure 3 Multiple glass opacities and consolidation shadows were found in both lungs (CT image of the chest on the 7th day of admission).

Delightedly, the temperature and thermal potential of the patient decreased significantly. The oxygenation index increased significantly, the percentage of neutrophilic percentage, and C-reactive protein and procalcitonin continued to decline. However, the patient experienced a high fever (39°C) again on the 7th day of admission. Then, the patient underwent lung CT examination again (Figure 3), indicating that the ground-glass lesions in both lungs were significantly increased. In contrast, the consolidation of both upper lungs was reduced compared to the previous examination. Considering the possibility of other infectious pathogens, the treatment was changed to an intravenous infusion of levofloxacin (0.5g qd) and omadacycline (0.1 qd). Subsequently, the patient's temperature gradually decreased, but a low fever remained. On the 8th day of admission, *Chlamydia* was detected with 9 specific reads (1.07% of relative abundance) by mNGS-DNA tests of BALF.

On the 11th day of admission, the patient was removed from the tracheal intubation and received high-flow sequential oxygen therapy. The patient's urine presented as flocculent material with a slightly cloudy color. A routine urine examination revealed piles of pus cells. Moreover, the urine culture of the patient revealed multi-drug resistant *Escherichia coli* (sensitive to ertapenem, imipenem, meropenem, amikacin, and furantoin, remaining resistant), indicating resistance to levofloxacin (mic \geq 8). Therefore, levofloxacin was adjusted to an intravenous infusion of meropenem (1g q8h). Consequently, the patient's condition improved, and she was discharged. The patient's condition and laboratory index also improved. The biochemical indicators of the patient's liver function throughout the treatment process showed a slow upward trend. Although hepatoprotective drugs were used, ALT and AST were still at twice the normal upper limit. She was later discharged on the 14th day of admission and transferred to a local hospital for further treatment.

Discussion

To our knowledge, only a few studies reported human pneumonia caused by *C. abortus*. Ortega et al⁵ reported the first atypical pneumonia related to *C. abortus* in Spain in 2016. The patient was a 47-year-old male, a veterinarian researcher with a focus on *Chlamydiae*. In 2020, a case of acute respiratory distress syndrome in a pregnant woman infected with *C. abortus* was reported in France.⁶ In 2022, a 66-year-old male patient with bloodstream infection and pneumonia caused by *C. abortus* and a 65-year-old male patient with septic shock caused by *C. abortus* infection were reported in China.^{7,8} In the same year, a case of severe pneumonia caused by *C. abortus* infection in pregnant women was reported in Switzerland.⁹ In 2023, China reported two cases of pneumonia caused by *C. abortus* in men diagnosed through mNGS. One of the patients received extracorporeal membrane oxygenation treatment for respiratory deterioration but unfortunately died.^{10,11} According to the reported cases of *C. abortus* infection pneumonia, the majority of patients are male, or

pregnant female patients. There have been no reports of cases of non-pregnant female patients. This case report is a 60-year-old female patient with no underlying diseases.

We should also note that this patient was co-infected with *H1N1*. Mixed infection may have exacerbated the complexity of this patient's condition and treatment. Qiao et al¹² also found that influenza bacterial co-infection was associated with high risk of severe illnesses. Klein et al¹³ demonstrated that *Chlamydia* was also an important pathogen in influenza co-infection. Moreover, a study conducted at a tertiary hospital in China, spanning data from 8 influenza seasons, revealed that the incidence of community-acquired influenza with bacterial co-infection was 19.6%, among which the incidence of *Chlamydia pneumoniae* was 4.9%.¹⁴ It was unclear whether the *C. abortus* infection in this patient was secondary to the *H1N1*. Notably, this report also highlights the importance of clinical vigilance for related patients in the future, emphasizing the need for close attention to the possibility of such secondary infections.

There are few reports of human infections caused by *C. abortus*, likely related to difficulties in identification. No serological testing has been approved for diagnosing *C. abortus* infection in humans.⁴ Other testing methods for pathogen identification include specimen culture and PCR. Unfortunately, certain limitations exist regarding detection time, rate of positivity, and specificity with these applications. NGS is a technology with high throughput parallel sequencing, which can sequence DNA or RNA fragments simultaneously and independently.¹⁵ Meanwhile, it is little affected by the antibiotics already used by the patient and is especially suitable for diagnosing novel, rare, and atypical etiologies of complicated infectious diseases.¹⁶ Several cases of *C. abortus* infection pneumonia reported in China were confirmed through mNGS.^{7,8,10,11} In this case, sputum, BALF, and blood samples were collected for smear and culture, except for a weak positive for *H1N1* antigen, while no pathogenic bacteria and fungi were found. Acid-fast staining of sputum and BALF was negative. However, we detected *C. abortus* in BALF through mNGS, and based on the patient's host factors, clinical symptoms, laboratory test results, imaging, and disease outcomes, we determined that the patient was suffering from severe pneumonia caused by *C. abortus* infection.

Until now, the source of human infection with *C. abortus* is not yet clear, and studies have shown that it may be related to direct or indirect exposure to the urine, milk, feces, and secretions of infected animals.^{5,9,17,18} A recent study also showed that infected patients have no apparent history of contact with livestock, indicating the possibility of other undetected infections.² A Polish study revealed the occurrence of *C. abortus* in chickens, albeit at a lower detection rate than that of *C. psittaci*.¹⁹ The latest cross-sectional epidemiological study from Belgium found that *C. abortus* was detected in 56.0% of the tested chicken flocks, indicating that *C. abortus* strains can be widespread among chickens.²⁰ Furthermore, that study also found *C. abortus* DNA from chicken caretakers. Fisher's exact test revealed a significant correlation between the infected backyard chickens and *C. abortus* in humans. In the present case, the patient's son reported a history of contact with poultry. Therefore, we suspect that *C. abortus* could be transmitted through poultry and could cause lung infection in female patients.

However, the specific pathway to human infection with *C. abortus* remains unclear. Likewise, individuals who are not immunocompromised can also be susceptible. In this female patient, the clinical manifestations of *C. abortus*-induced pulmonary infection were non-specific and manifested with fever, cough, and limb weakness as the main symptoms. However, the disease rapidly and quickly progressed to dyspnea. Auxiliary examination exhibited respiratory failure, hyponatremia, hypokalemia, anemia, hypoproteinemia, and abnormal liver function. Chest CT showed multiple patchy high-density shadows, consolidation shadows, and bilateral pleural effusion. Similar to clinical manifestations of *Chlamydia psittaci* infection,²¹ human *C. abortus* pneumonia is rare but may have a life-threatening condition. As we reported, the patient rapidly experienced progresses to dyspnea and circulatory instability.

Therefore, clinical physicians must make timely diagnoses and prescribe the correct antibiotic treatment. *Chlamydia* is a gram-negative intracellular bacterium that contains a thin peptidoglycan cell wall and an outer membrane containing lipopolysaccharides. Importantly, beta-lactams are effective on *Chlamydial* elementary bodies. However, they have been linked to the development of aberrant bodies (*Chlamydia* persistence), which is why they are not recommended for treatment.²² There are no treatment guidelines for *C. abortus* infections in humans, and the current treatment mainly refers to the recommendations for *C. psittaci* infection. Tetracycline antibiotics are considered the most effective treatment for *C. psittaci* infection, with the oral dosage form for mild cases and intravenous injection for severe cases.²³ Moreover, macrolide and quinolone antibiotics are alternative agents.^{24,25} Fang et al²⁶ reported that the new

tetracycline drug, omadacycline, will become a new option for treating severe *C. psittaci* infection due to its safety and the advantage of not requiring dose adjustment in special populations. Importantly, the clinical outcome of this patient showed that the combination of omadacycline and moxifloxacin had a satisfactory therapeutic effect on severe pneumonia with *C. abortus* infection.

Conclusion

Infections of *C. abortus* co-infected with *H1N1* can result in severe respiratory distress, disturbance of water and electrolyte balance, and abnormal liver function, requiring timely diagnosis and correct use of antibiotics by clinicians. Our report also highlights the importance of mNGS as a diagnostic tool for rare pathogens. Combining tetracycline and quinolone is a practical choice for treating severe pneumonia with *C. abortus* infection. Further research is needed to identify the transmission routes of *C. abortus* infection and explore an effective clinical diagnostic model to establish scientific prevention guidelines and precise clinical treatment strategies.

Data Sharing Statement

The dataset supporting the conclusions of this article is included in the article. Specific laboratory or imaging data are available from the corresponding author on reasonable request.

Ethics Approval and Consent to Participate

The study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of Xiangya Hospital, Central South University (No.ChiCTR2100046040). Written informed consent was obtained from the patient's son for publication of this case report.

Consent for Publication

The patient provided oral informed consent for publication of the clinical details including lung CT images. Written informed consent was provided by the patient's relatives (patient's son) for publication of the case details and images. The patient's verbal informed consent and her son's written informed consent for publication of case-related details were witnessed and documented. Details of the case can be published without institutional approval.

Acknowledgments

We are grateful for the support and dedication of all staff in the respiratory ICU department of Xiangya Hospital of Central South University. The authors thank AiMi Academic Services (www.aimieditor.com) for English language editing and review services.

Funding

This work was funded by The Research Project of Xi'an Municipal Health Commission (2024ms02). The funders had no role in the study design, data collection and analyses, decision to publish, or preparation of the manuscript.

Disclosure

No conflict of interest exists in the submission of this manuscript, and the manuscript has been approved by all authors for publication.

References

1. Sachse K, Bavoi PM, Kaltenboeck B. et al. Emendation of the family Chlamydiaceae: proposal of a single genus, Chlamydia, to include all currently recognized species. *Syst Appl Microbiol.* 2015;38(2):99–103. doi:10.1016/j.syapm.2014.12.004
2. Xie G, Hu Q, Cao X, et al. Clinical identification and microbiota analysis of Chlamydia psittaci- and Chlamydia abortus- pneumonia by metagenomic next-generation sequencing. *Front Cell Infect Microbiol.* 2023;13:1157540. doi:10.3389/fcimb.2023.1157540
3. Tagini F, Greub G. Infections à chlamydias: épidémiologie, pathogénèse, diagnostic et traitements [Chlamydial infections: epidemiology, pathogenesis, diagnosis and treatments]. *Rev Med Suisse.* 2018;14(618):1620–1625.

4. Turin L, Surini S, Wheelhouse N, Rocchi MS. Recent advances and public health implications for environmental exposure to *Chlamydia abortus*: from enzootic to zoonotic disease. *Vet Res.* 2022;53(1):37. doi:10.1186/s13567-022-01052-x
5. Ortega N, Caro MR, Gallego MC, et al. Isolation of *Chlamydia abortus* from a laboratory worker diagnosed with atypical pneumonia. *Ir Vet J.* 2016;69(1):8. doi:10.1186/s13620-016-0067-4
6. Pichon N, Guindre L, Laroucau K, Cantaloube M, Nallatamby A, Parreau S. *Chlamydia abortus* in pregnant woman with acute respiratory distress syndrome. *Emerg Infect Dis.* 2020;26(3):628–629. doi:10.3201/eid2603.191417
7. Zhu C, Lv M, Huang J, et al. Bloodstream infection and pneumonia caused by *Chlamydia abortus* infection in China: a case report. *BMC Infect Dis.* 2022;22(1):181. doi:10.1186/s12879-022-07158-z
8. Liu M, Wen Y, Ding H, Zeng H. Septic shock with *Chlamydia abortus* infection. *Lancet Infect Dis.* 2022;22(6):912. doi:10.1016/S1473-3099(21)00756-8
9. Imkamp F, Albini S, Karbach M, et al. Zoonotic *Chlamydiae* as rare causes of severe pneumonia. *Swiss Med Wkly.* 2022;11(152):w30102. doi:10.4414/SMW.2022.w30102
10. Huang J, Liu C, Zhou Z, et al. Extracorporeal membrane oxygenation in severe acute respiratory distress syndrome caused by *Chlamydia abortus*: a case report. *Infect Drug Resist.* 2023;16:3893–3901. doi:10.2147/IDR.S411331
11. Gong F, Chen Z, Chang J, et al. Metagenomic next-generation sequencing contributes to the diagnosis of pneumonia caused by *Chlamydia abortus* in a male patient: case report and literature review. *Infect Drug Resist.* 2023;16:3463–3468. doi:10.2147/IDR.S407741
12. Qiao M, Moyes G, Zhu F, Li Y, Wang X. The prevalence of influenza bacterial co-infection and its role in disease severity: a systematic review and meta-analysis. *J Glob Health.* 2023;13:04063. doi:10.7189/jogh.13.04063
13. Klein EY, Monteforte B, Gupta A, et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. *Influenza Other Respir Viruses.* 2016;10(5):394–403. doi:10.1111/irv.12398
14. Teng F, Liu X, Guo SB, et al. Community-acquired bacterial co-infection predicts severity and mortality in influenza-associated pneumonia admitted patients. *J Infect Chemother.* 2019;25(2):129–136. doi:10.1016/j.jiac.2018.10.014
15. Goldberg B, Sichtig H, Geyer C, Ledebner N, Weinstock GM. Making the leap from research laboratory to clinic: challenges and opportunities for next-generation sequencing in infectious disease diagnostics. *mBio.* 2015;6(6):e01888–15. doi:10.1128/mBio.01888-15
16. Miao Q, Ma Y, Wang Q, et al. Microbiological diagnostic performance of metagenomic next-generation sequencing when applied to clinical practice. *Clin Infect Dis.* 2018;67(suppl_2):S231–S240. doi:10.1093/cid/ciy693
17. Meijer A, Brandenburg A, de Vries J, Beentjes J, Roholl P, Dercksen D. *Chlamydia abortus* infection in a pregnant woman associated with indirect contact with infected goats. *Eur J Clin Microbiol Infect Dis.* 2004;23(6):487–490. doi:10.1007/s10096-004-1139-z
18. Burgener AV, Seth-Smith HMB, Kern-Baumann S, et al. A case study of zoonotic *Chlamydia abortus* infection: diagnostic challenges from clinical and microbiological perspectives. *Open Forum Infect Dis.* 2022;9(10):ofac524. doi:10.1093/ofid/ofac524
19. Szymańska-Czerwińska M, Mitura A, Zaręba K, Schnee C, Koncicki A, Niemczuk K. Poultry in Poland as *Chlamydiaceae* carrier. *J Vet Res.* 2017;61(4):411–419. doi:10.1515/jvetres-2017-0072
20. De Meyst A, De Clercq P, Porrez J, et al. Belgian cross-sectional epidemiological study on zoonotic avian *Chlamydia* spp. in chickens. *Microorganisms.* 2024;12(1):193. doi:10.3390/microorganisms12010193
21. Fang C, Xu L, Lu J, Tan H, Lin J, Zhao Z. Clinical characteristics of *Chlamydia psittaci* pneumonia confirmed by metagenomic next-generation sequencing. *Clin Lab.* 2022;68(11). doi:10.7754/Clin.Lab.2022.220139
22. Kohlhoff SA, Hammerschlag MR. Treatment of *Chlamydial* infections: 2014 update. *Expert Opin Pharmacother.* 2015;16(2):205–212. doi:10.1517/14656566.2015.999041
23. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America[J]. *Am J Respir Crit Care Med.* 2019;200(7):e45–e67. doi:10.1164/rccm.201908-1581ST
24. Balsamo G, Maxted AM, Midla JW, et al. Compendium of measures to control *Chlamydia psittaci* infection among humans (Psittacosis) and pet birds (Avian Chlamydiosis), 2017. *J Avian Med Surg.* 2017;31(3):262–282. doi:10.1647/217-265
25. Teng XQ, Gong WC, Qi TT, et al. Clinical analysis of metagenomic next-generation sequencing confirmed *Chlamydia psittaci* pneumonia: a case series and literature review. *Infect Drug Resist.* 2021;14:1481–1492. doi:10.2147/IDR.S305790
26. Fang C, Xu L, Tan J, Tan H, Lin J, Zhao Z. Omadacycline for the treatment of severe *Chlamydia psittaci* pneumonia complicated with multiple organ failure: a case report. *Infect Drug Resist.* 2022;15:5831–5838. doi:10.2147/IDR.S384296

Infection and Drug Resistance

Dovepress

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>